Dmitry Balyasny’s SAB Biotherapeutics SABS Stock Holding History

Dmitry Balyasny’s Portfolio SABS Stock Details SABS Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2026 Q2	$14.7M	Hold	3,760,439	–	–	0.02%	882
2026 Q1	$14.4M	Buy	3,760,439 +3,285,000	+691%	+$13.1M	0.02%	840
2025 Q4	$1.78M	Buy	+475,439	New	+$1.56M	﹤0.01%	1925

Other funds holding SABS

Caligan Partners New York $2.13B AUM 758.65% 1-Year Est. Return

Vivo Capital Palo Alto, California $1.1B AUM 799.93% 1-Year Est. Return

Perceptive Advisors New York $6.66B AUM 360.84% 1-Year Est. Return

Adage Capital Partners Boston, Massachusetts $71.3B AUM 56.8% 1-Year Est. Return

RCM

RA Capital Management Boston, Massachusetts $11.5B AUM 168.77% 1-Year Est. Return

BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return

Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM

Commodore Capital New York $1.68B AUM 375.52% 1-Year Est. Return

Millennium Management New York $276B AUM 44.8% 1-Year Est. Return

SSC

Spruce Street Capital New York $510M AUM

Dmitry Balyasny's SABS Position: Q2 2026 in Review

Dmitry Balyasny held its SAB Biotherapeutics (SABS) position steady in Q2 2026 at 3,760,439 shares worth $14.7M. The position accounts for 0.02% of the portfolio, ranked #882.

Dmitry Balyasny first reported a position in SABS in Q4 2025 and has held it in 3 quarters since. 86 funds tracked by Wall St. Rank hold SABS as of Q2 2026.

Dmitry Balyasny held 3,760,439 shares of SAB Biotherapeutics worth $14.7M as of Q2 2026.
Dmitry Balyasny left its SAB Biotherapeutics share count unchanged in Q2 2026.
SAB Biotherapeutics made up 0.02% of Dmitry Balyasny's portfolio in Q2 2026, its #882 holding.
Dmitry Balyasny first reported a position in SAB Biotherapeutics in Q4 2025 and has held it in 3 quarters since.
86 funds tracked by Wall St. Rank held SAB Biotherapeutics as of Q2 2026.

Based on Balyasny Asset Management's 13F filing for Q2 2026, filed 14 Aug 2026.